Peptide Inhibitor of Complement C1 (PIC1) Inhibits Growth of Pathogenic Bacteria
Peptide Inhibitor of Complement C1 (PIC1) is a family of 15 amino acid peptides that inhibit complement activation via the classical and lectin pathways and inhibit myeloperoxidase. PIC1 peptides were originally derived from a region of limited homology with defensin human neutrophil peptide 1 (HNP-1). Despite having undergone extensive rearrangements of amino acid sequence subsequently, PIC1 peptides retain the defensin-like characteristics of being cysteine rich and amphiphilic. To date, defensin-like antimicrobial activity for PIC1 has not been explored. Here we report the antimicrobial activity of PIC1 for multiple pathogenic bacteria tested in minimum inhibitory concentration (MIC)-type assays. PIC1variant PA-dPEG24 was found to have antimicrobial activity against Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Neisseria meningitidis, Neisseria gonorrhoeae, Gardnerella vaginalis, and Prevotella bivia. Confocal microscopy demonstrated PIC1 localized to the surface of P. aeruginosa and S. aureus consistent with the defensins. Testing PIC1 variants with amino acid substitutions revealed differences in complement inhibition and antimicrobial effects suggesting these occur via independent mechanisms. PIC1 inhibited P. aeruginosa growth in normal human serum suggesting the antimicrobial effect was dominant versus the survival benefit resulting from complement inhibition. In summary, these experiments demonstrate that PIC1 peptides have broad antimicrobial activity against pathogenic bacteria similar to defensins.
KeywordsDefensin Antibiotic Complement Staphylococcus Pseudomonas Neisseria
This work was supported in part by grants from Eastern Virginia Medical School and the Children’s Health Foundation (The Children’s Hospital of The King’s Daughters). Advice for certain bacterial growth conditions was kindly provided by the Clinical Microbiology Laboratory staff of The Children’s Hospital of The King’s Daughters and Dr. Dayle Daines at Old Dominion University.
Compliance with Ethical Standards
Conflict of interest
The authors declare no conflicts of interest.
- Brier S, Pflieger D, Le Mignon M, Bally I, Gaboriaud C, Arlaud GJ, Daniel R (2010) Mapping surface accessibility of the C1r/C1s tetramer by chemical modification and mass spectrometry provides new insights into assembly of the human C1 complex. J Biol Chem 285:32251–32263. https://doi.org/10.1074/jbc.M110.149112 CrossRefGoogle Scholar
- Frank MM, Atkinson JP (2001) Complement system. In: Austen KF, Frank MM, Atkinson JP, Cantor H (eds) Samter’s immunologic disease. Lippincott Williams and Wilkins, New York, pp 281–298Google Scholar
- Larsen B (1993) Vaginal flora in health and disease Clinical. Obstet Gynecol 36:107–121Google Scholar
- van den Berg RH, Faber-Krol MC, van Wetering S, Hiemstra PS, Daha MR (1998) Inhibition of activation of the classical pathway of complement by human neutrophil defensins. Blood 92:3898–3903Google Scholar
- Zalenskaya IA et al (2015) Gene expression profiling of human vaginal cells in vitro discriminates compounds with pro-inflammatory and mucosa-altering properties: novel biomarkers for preclinical testing of hiv microbicide candidates. PLoS ONE 10:e0128557. https://doi.org/10.1371/journal.pone.0128557 CrossRefGoogle Scholar